Main content

    Brain Cancer Clinical Trials

    CPMC Cancer Services

    Oncology / Cancer Clinical Trials Main Page | Adult Clinical Trials Main Page

    Further protocol information can be found on the links below at ClinicalTrials.gov


    Active Trials

    Title: Randomized Phase II Trial of Concurrent Bevacizumab and Re-Irradiation Versus Bevacizumab Alone as Treatment for Recurrent Glioblastoma
    Description: This trial studies how well bevacizumab with or without radiation therapy works in treating patients with recurrent glioblastoma
    Investigator: NCI - National Cancer Institute
    Eligibility: Subjects, 18 y/o and older, with a histopathologically proven diagnosis of glioblastoma or variants (gliosarcoma, giant cell glioblastoma etc)
    Status: Please contact site for study status
    Contact: Peter Gasper, 415-600-3472, Email: GasperJP@cpmcri.org about Study RTOG -1205

    Title: A Phase III Trial of Post-Surgical Stereotactic Radiosurgery (SRS) Compared With Whole Brain Radiotherapy (WBRT) for Resected Metastatic Brain Disease
    Description: This trial studies how well stereotactic radiosurgery works compared to whole-brain radiation therapy in treating patients with brain metastases that have been removed by surgery
    Investigator: NCI - National Cancer Institute
    Eligibility: Subjects, 18 y/o and older, with four or fewer brain metastases (as defined on the pre-operative MRI brain scan) and status post resection of one of the lesions
    Status: Please contact site for study status
    Contact: Peter Gasper, 415-600-3472, Email: GasperJP@cpmcri.org about Study NCCTG-N107C

    Title: A Phase III Randomized, Double-Blind Placebo Controlled Study of Armodafinil (Nuvigil®) To Reduce Cancer-Related Fatigue in Patients With High Grade Glioma
    Description: This randomized phase III trial studies armodafinil to see how well it works in reducing cancer-related fatigue in patients with high grade glioma. Armodafinil may help relieve fatigue in patients with high grade glioma
    Investigator: NCI - National Cancer Institute
    Eligibility: Subjects, 18 y/o and older, diagnosed with glioblastoma, gliosarcoma, small cell or large cell glioblastoma, glioblastoma with oligo features, glioblastoma with primitive neuroectodermal tumor-like components (GBM-PNET) features, anaplastic astrocytoma, anaplastic oligodendroglioma, or anaplastic oligoastrocytoma who are clinically stable and have completed radiation therapy > 21 days and ≤ 24 months prior to enrollment
    Status: Please contact site for study status
    Contact: Peter Gasper, 415-600-3472, Email: GasperJP@cpmcri.org about Study Alliance A221101

    Title: Randomized Phase II Trial of Hypofractionated Dose-Escalated Photon IMRT or Proton Beam Therapy Versus Conventional Photon Irradiation With Concomitant and Adjuvant Temozolomide in Patients With Newly Diagnosed Glioblastoma
    Description: This randomized phase II trial studies how well dose-escalated photon intensity-modulated radiation therapy (IMRT) or proton beam radiation therapy works compared with standard-dose radiation therapy when given with temozolomide in patients with newly diagnosed glioblastoma
    Investigator: NCI - National Cancer Institute
    Eligibility: Subjects, 18 y/o and older, with a histologically proven diagnosis of glioblastoma (World Health Organization [WHO] grade IV) confirmed by central review
    Status: Please contact site for study status
    Contact: Peter Gasper, 415-600-3472, Email: GasperJP@cpmcri.org about Study NRG BN001

    Title: A Phase II Randomized Trial Comparing the Efficacy of Heat Shock Protein-Peptide Complex-96 (HSPPC-96) (NSC #725085, ALLIANCE IND # 15380) Vaccine Given With Bevacizumab Versus Bevacizumab Alone in the Treatment of Surgically Resectable Recurrent Glioblastoma Multiforme (GBM)
    Description: This randomized phase II trial studies how well giving vaccine therapy with or without bevacizumab works in treating patients with recurrent glioblastoma multiforme that can be removed by surgery
    Investigator: NCI - National Cancer Institute
    Eligibility: Subjects, 18 y/o and older, with a prior histologic diagnosis of GBM at first occurrence
    Status: Please contact site for study status
    Contact: Peter Gasper, 415-600-3472, Email: GasperJP@cpmcri.org about Study Alliance A071101

    • updated July 2015

    Back to top